|
| DGDispatch
SABCS: Clodronate Reduces Morbidity Even Among Patients With Breast Cancer
Relapse
By Charlene Laino
SAN ANTONIO, TX -- December 14, 2004 -- Addition of the bisphosphonate
clodronate to standard adjuvant breast cancer therapy reduces morbidity and
mortality, even among patients who relapse, a retrospective analysis of a
randomized, double-blind, placebo-controlled study of patients with primary
operable Stage I-III breast cancer.
Patients who developed bone metastases while receiving adjuvant oral clodronate
lived a median of approximately 2.5 years longer compared with patients
receiving placebo, said Trevor Powles, MD, professor emeritus of breast
oncology, Royal Marsden Hospital, London, United Kingdom.
Reporting here on December 9th at the 27th San Antonio Breast Cancer Symposium
(SABCS), Dr. Powles said that patients on adjuvant oral clodronate therapy had
a median survival of 2,107 days, compared with a median of 1,229 days for
patients on placebo.
The new study builds on a previous analysis of the same data, presented at ASCO
2004, which showed that oral clodronate reduced significantly the rate of bone
events and mortality among patients with primary operable Stage I-III breast
cancer compared with placebo, he said.
To determine whether patients who had cancer relapse developed resistance to
bisphosphonate treatment, the researchers conducted a new analysis that focused
on the 51 women on clodronate and 73 on placebo who developed bone metastases
during the 5-year study period.
The overall incidence of skeletal-related events was 56.9% on adjuvant oral
clodronate and 72.6% on placebo (P <.01). The most striking differences were
seen in the need for radiation (47% vs. 64%) and the development of
non-vertebral skeletal fractures (12% vs. 22%), Dr. Powles said.
"There's a spillover effect," he said. "Even though patients relapsed and
previously had a bisphosphonate, they still do better."
Schering AG helped fund the study.
[Presentation title: "Oral Clodronate (BONEFOSŪ) Reduces Skeletal Complications
and Mortality in Breast Cancer Patients With Bone Metastases: Retrospective
Analysis of Patients From a Randomized, Placebo-Controlled Trial." Abstract
3056]
--------------------------------------------------------------------------
--------
http://tinyurl.com/3ngso
In these reactions iron plays an important role suggesting that the selective
in vitro antioxidant properties of the bisphosphonates are due to their iron
chelating characteristics.
PMID: 14741688 [PubMed - in process]
------------------------------------------------------------------------------
Who loves ya.
Tom
Jesus Was A Vegetarian! http://jesuswasavegetarian.7h.com
Man Is A Herbivore! http://pages.ivillage.com/ironjustice/manisaherbivore
DEAD PEOPLE WALKING http://pages.ivillage.com/ironjustice/deadpeoplewalking
|
|